Related Experiment Video
Updated: Aug 29, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
ROBO3s: a novel ROBO3 short isoform promoting breast cancer aggressiveness
Marcel Werner1,2, Anna Dyas1,3,4, Iwan Parfentev5
1Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Göttingen, Germany.
Abstract:
Basal-like breast cancer (BLBC) is a highly aggressive breast cancer subtype frequently associated with poor prognosis. Due to the scarcity of targeted treatment options, conventional cytotoxic chemotherapies frequently remain the standard of care. Unfortunately, their efficacy is limited as BLBC malignancies rapidly develop resistant phenotypes. Using transcriptomic and proteomic approaches in human and murine BLBC cells, we aimed to elucidate the molecular mechanisms underlying the acquisition of aggressive and chemotherapy-resistant phenotypes in these mammary tumors. Specifically, we identified and characterized a novel short isoform of Roundabout Guidance Receptor 3 (ROBO3s), upregulated in BLBC in response to chemotherapy and encoding for a protein variant lacking the transmembrane domain. We established an important role for the ROBO3s isoform, mediating cancer stem cell properties by stimulating the Hippo-YAP signaling pathway, and thus driving resistance of BLBC cells to cytotoxic drugs. By uncovering the conservation of ROBO3s expression across multiple cancer types, as well as its association with reduced BLBC-patient survival, we emphasize its potential as a prognostic marker and identify a novel attractive target for anti-cancer drug development.
Insights
A novel Roundabout Guidance Receptor 3 short isoform (ROBO3s) drives aggressive basal-like breast cancer (BLBC) and chemotherapy resistance by activating the Hippo-YAP pathway. ROBO3s is a potential prognostic marker and therapeutic target for BLBC.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Basal-like breast cancer (BLBC) is aggressive with poor prognosis.
- Limited targeted therapies necessitate chemotherapy, but resistance is common.
- Understanding resistance mechanisms is crucial for BLBC treatment.
Purpose of the Study:
- To identify molecular mechanisms of aggressive and chemotherapy-resistant phenotypes in BLBC.
- To characterize a novel Roundabout Guidance Receptor 3 short isoform (ROBO3s).
- To investigate the role of ROBO3s in BLBC chemoresistance and cancer stem cell properties.
Main Methods:
- Transcriptomic and proteomic analyses in human and murine BLBC cells.
- Identification and characterization of the ROBO3s isoform.
- Investigation of ROBO3s function in mediating cancer stem cell properties and Hippo-YAP pathway activation.
- Analysis of ROBO3s expression across cancer types and its association with patient survival.
Main Results:
- A novel, short isoform of Roundabout Guidance Receptor 3 (ROBO3s) was identified, lacking a transmembrane domain.
- ROBO3s is upregulated in BLBC, particularly in response to chemotherapy.
- ROBO3s promotes cancer stem cell properties and stimulates the Hippo-YAP signaling pathway.
- ROBO3s expression is conserved across cancer types and correlates with reduced BLBC patient survival.
Conclusions:
- The ROBO3s isoform plays a critical role in driving BLBC aggressiveness and chemotherapy resistance.
- ROBO3s mediates these effects by activating the Hippo-YAP signaling pathway.
- ROBO3s represents a promising prognostic marker and a novel therapeutic target for BLBC treatment.
More Related Videos
Related Concept Videos
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Cancer
Cancer Prevention
Some...

